glibenclamide
Small moleculeexperimental
Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended for use by itself in type 1 diabetes. It is taken by mouth. — Wikipedia
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
1
Earliest trial started Aug 31, 2019 (NCT03954041)
Timeline
Indications
Approved for
Mechanism of action
KCNJ1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlibenclamide ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221799 | Phase 1 | Sep 1, 2026 | University of Maryland |
| NCT05688332 | Phase 3 | Aug 31, 2023 | University of Zambia, University Teaching Hospital, Lusaka, Zambia |
| NCT05687500 | Phase 2 | May 20, 2023 | Assistance Publique - Hôpitaux de Paris |
| NCT05148403 | Phase 1/Phase 2 (Phase 2) | Oct 22, 2021 | Capital Medical University |
| NCT05137678 | Phase 4 | Sep 25, 2021 | Capital Medical University |
| NCT04960657 | N/A | Oct 20, 2020 | University of Copenhagen |
| NCT04231617 | N/A | Jan 20, 2020 | University of Copenhagen |
| NCT03954041 | Phase 2 | Aug 31, 2019 | Biogen |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 2 | 2 | 2021 |
| University of Copenhagen | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Biogen | For profit | 1 | 1 | 1 | 2019 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2026 |
| University of Zambia | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University Teaching Hospital, Lusaka, Zambia | Academic/Hospital | 1 | 0 | 1 | 2023 |
7 organizations
Page 1 / 1